The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
秋风
无极微光
aaaa
DW
蓝天
愉快的真
潇洒的惋清
Criminology34
xing_xing
lalala
鹤暮
DOC_XIONG
嘻嘻哈哈
科研狗
GingerF
痴情的朋友
贪玩的秋柔
小薛
芽芽
Dean
皖公网安备34019202002308
